Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genome-wide Loss-of-Function Screen Reveals an Important Role for the Proteasome in HDAC Inhibitor-Induced Apoptosis
Susan Fotheringham, Mirjam T. Epping, Lindsay Stimson, et al.
Cancer Cell (2009) Vol. 15, Iss. 1, pp. 57-66
Open Access | Times Cited: 127

Showing 1-25 of 127 citing articles:

Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Katrina J. Falkenberg, Ricky W. Johnstone
Nature Reviews Drug Discovery (2014) Vol. 13, Iss. 9, pp. 673-691
Closed Access | Times Cited: 1372
New and emerging HDAC inhibitors for cancer treatment
Alison C. West, Ricky W. Johnstone
Journal of Clinical Investigation (2014) Vol. 124, Iss. 1, pp. 30-39
Open Access | Times Cited: 1253
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Omar Khan, Nicholas B. La Thangue
Immunology and Cell Biology (2011) Vol. 90, Iss. 1, pp. 85-94
Open Access | Times Cited: 432
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Julia M. Wagner, Björn Hackanson, Michael Lübbert, et al.
Clinical Epigenetics (2010) Vol. 1, Iss. 3-4, pp. 117-136
Open Access | Times Cited: 385
HDAC inhibitor‐based therapies: Can we interpret the code?
Maria I. New, Heidi Olzscha, Nicholas B. La Thangue
Molecular Oncology (2012) Vol. 6, Iss. 6, pp. 637-656
Open Access | Times Cited: 300
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
Nicholas B. La Thangue, David Kerr
Nature Reviews Clinical Oncology (2011) Vol. 8, Iss. 10, pp. 587-596
Closed Access | Times Cited: 298
Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Prithviraj Bose, Yun Dai, Steven Grant
Pharmacology & Therapeutics (2014) Vol. 143, Iss. 3, pp. 323-336
Open Access | Times Cited: 248
Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy
M. Janaki Ramaiah, Anjana Devi Tangutur, M. Rajasekhar Reddy
Life Sciences (2021) Vol. 277, pp. 119504-119504
Closed Access | Times Cited: 217
Targeting tumour-supportive cellular machineries in anticancer drug development
Matthias Dobbelstein, Ute M. Moll
Nature Reviews Drug Discovery (2014) Vol. 13, Iss. 3, pp. 179-196
Closed Access | Times Cited: 208
Immune cell topography predicts response to PD-1 blockade in cutaneous T cell lymphoma
Darci J. Phillips, Magdalena Matusiak, Belén Rivero‐Gutiérrez, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 157
Histone Deacetylase Inhibitors
Xujun Ma, Hany Ezzeldin, Robert B. Diasio
Drugs (2009) Vol. 69, Iss. 14, pp. 1911-1934
Closed Access | Times Cited: 227
Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group
Winnie Yeo, Hyun Cheol Chung, Stephen L. Chan, et al.
Journal of Clinical Oncology (2012) Vol. 30, Iss. 27, pp. 3361-3367
Open Access | Times Cited: 185
Histone Deacetylase Inhibitors In The Treatment Of Cancer: Overview And Perspectives
Giuseppe Giannini, Walter Cabri, Caterina Fattorusso, et al.
Future Medicinal Chemistry (2012) Vol. 4, Iss. 11, pp. 1439-1460
Closed Access | Times Cited: 163
Epigenetic cancer therapy: rationales, targets and drugs
Maria Rius, Frank Lyko
Oncogene (2011) Vol. 31, Iss. 39, pp. 4257-4265
Open Access | Times Cited: 158
Multiple roles of class I HDACs in proliferation, differentiation, and development
Nina Reichert, Mohamed-Amin Choukrallah, Patrick Matthias
Cellular and Molecular Life Sciences (2012) Vol. 69, Iss. 13, pp. 2173-2187
Open Access | Times Cited: 157
HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy
Omar Khan, Susan Fotheringham, Victoria Wood, et al.
Proceedings of the National Academy of Sciences (2010) Vol. 107, Iss. 14, pp. 6532-6537
Open Access | Times Cited: 147
Endogenous modulators and pharmacological inhibitors of histone deacetylases in cancer therapy
Sarah Spiegel, Sheldon Milstien, Steven Grant
Oncogene (2011) Vol. 31, Iss. 5, pp. 537-551
Open Access | Times Cited: 138
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
Michael Dickinson, Ricky W. Johnstone, H. Miles Prince
Investigational New Drugs (2010) Vol. 28, Iss. S1, pp. 3-20
Open Access | Times Cited: 137
Histone deacetylases are critical targets of bortezomib-induced cytotoxicity in multiple myeloma
Jiro Kikuchi, Taeko Wada, Rumi Shimizu, et al.
Blood (2010) Vol. 116, Iss. 3, pp. 406-417
Open Access | Times Cited: 125
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment
Till Milde, Marco Lodrini, Larissa Savelyeva, et al.
Journal of Neuro-Oncology (2012) Vol. 110, Iss. 3, pp. 335-348
Closed Access | Times Cited: 120
Entinostat: a promising treatment option for patients with advanced breast cancer
Roisín M. Connolly, Michelle A. Rudek, Richard Piekarz
Future Oncology (2017) Vol. 13, Iss. 13, pp. 1137-1148
Open Access | Times Cited: 118
The application of histone deacetylases inhibitors in glioblastoma
Rui Chen, Mengxian Zhang, Yangmei Zhou, et al.
Journal of Experimental & Clinical Cancer Research (2020) Vol. 39, Iss. 1
Open Access | Times Cited: 84
HDAC inhibitor-based therapies and haematological malignancy
Lindsay Stimson, Victoria Wood, Omar Khan, et al.
Annals of Oncology (2009) Vol. 20, Iss. 8, pp. 1293-1302
Open Access | Times Cited: 130
Histone deacetylases and epigenetic therapies of hematological malignancies
Ciro Mercurio, Saverio Minucci, Pier Giuseppe Pelicci
Pharmacological Research (2010) Vol. 62, Iss. 1, pp. 18-34
Closed Access | Times Cited: 124
Chemopreventive Agent 3,3′-Diindolylmethane Selectively Induces Proteasomal Degradation of Class I Histone Deacetylases
Yongming Li, Xia Li, Bin Guo
Cancer Research (2010) Vol. 70, Iss. 2, pp. 646-654
Open Access | Times Cited: 113
Page 1 - Next Page

Scroll to top